Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States
Pharmacoepidemiology and Drug Safety2018Vol. 28(1), pp. 80–89
Citations Over TimeTop 10% of 2018 papers
Wei‐Hsuan Lo‐Ciganic, Julie M. Donohue, Joo Yeon Kim, Elizabeth E. Krans, Bobby L. Jones, David Kelley, A. Everette James, Marian Jarlenski
Abstract
Six buprenorphine treatment trajectories during pregnancy were identified in this population-based Medicaid cohort, with 25% of women initiating buprenorphine late during pregnancy. Understanding trajectories of buprenorphine use and factors associated with discontinuation/nonadherence may guide integration of behavioral treatment with obstetrical/gynecological care to improve buprenorphine treatment during pregnancy.
Related Papers
- → Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment(2017)165 cited
- → ‘Matters-of-concern’ associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study(2024)12 cited
- → Case series: Voluntary discontinuation of sublingual buprenorphine treatment for opioid use disorder using extended‐release buprenorphine(2023)6 cited
- → Can buprenorphine be used for opioid use disorder during pregnancy?(2021)
- → Opioid Use Disorder Education for Students and the Future of Opioid Overdose Treatment (Preprint)(2022)